Hematologic Cancers News Today

Blood cancer or hematological cancer is cancer involving the blood cells and affects their normal formation as well as function. Test your knowledge on blood cancer and learn more about blood cancer.

The expert panel shares emerging data on an engineered, allogeneic cell-based therapy administered as part of conditioning for allo-HSCT in patients with relapsed, refractory, or high-risk hematologic cancers.

An overview of promising novel cellular therapies showing efficacy against hematologic cancers in early-phase clinical trials.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.

Another study has linked glyphosate, the primary chemical used by Monsanto in its Roundup herbicide, to increases in cancer as well as alterations to DNA and oxidative stress. The study, which [...]

/PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced...

/PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform...

/PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform...

Share this article Share this article ResearchAndMarkets.coms offering. The scientific community has been pursuing research for the development of CAR T-cell therapy for over a century. Immunotherapy has emerged as an innovative treatment option over decades, as it harnesses the patients immune system to attack cancer. The global market for CAR T-cell therapy is predicted to grow at a CAGR of 44.79% over the forecast period 2020-2030. The market is driven by certain factors, which include incre...